Clinical Study

Calgb30610- Phase III Comparison Of Thoracic Radiotherapy Regimens In Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin And Etoposide

Posted Date: May 15, 2019

  • Investigator: Kevin Redmond
  • Specialties: Cancer, Lung Cancer, Oncology
  • Type of Study: Drug

The goal of this study is To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3 weeks) in patients with limited stage small cell lung cancer.


To Be Eligible: Diagnosed With Small Cell Lung Cancer, >18 Years Of Age, No Prior Treatment For Sclc, Nonpregnant/Nonbreastfeeding


Calgb30610, Limited Small Cell L, Lung Cancer, Sclc, Thoracic Cancer

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.